Nintedanib has been shown to slow disease progression in patients with idiopathic pulmonary fibrosis (IPF). It was approved by the National Institute for Health and Care Excellence (NICE) in January 2016 for I...
Παρασκευή 3 Νοεμβρίου 2017
Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Abstract Multi component tympanometry is not widely used in clinics due lack of evidence supporting its usefulness. The present study was ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.